Muhammad Tayyub, Khizar Raheel, Fizza Raheel, Dr Imran Aslam, Abdurakhmonova Zamira Ergashboevna (1)
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were first used to lower blood glucose in type 2 diabetes. Nevertheless, increasing data from heart failure–specific trials and from large cardiovascular outcome trials have proven that the favorable effects of SGLT2 inhibitors are not related to their glucose-lowering effect. These drugs have consistently been shown to reduce rates of hospitalization for heart failure, cardiovascular mortality, and progression of renal disease in both diabetic and non-diabetic patients. Retrospective review summarizes up-to-date evidence of SGLT2 inhibitors in reducing the risk of heart failure. The purpose of this article is to present recent research articles on benefits, mechanisms, major clinical trials, and near-term practical applications that are pertinent to current cardiovascular care. Knowledge of these pleiotropic effects is crucial for identifying the optimal candidates and integrating SGLT2 inhibitors into routine cardiology practice
1. Zinman B, wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N Engl J Med. 2015; 373:2117-2128.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type
2 diabetes. N Engl J Med. 2017; 377:644-657.
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
N Engl J Med. 2019; 380:347-357.
4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and
reduced ejection fraction. N Engl J Med. 2019; 381:1995-2008.
5. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart
failure. N Engl J Med. 2020; 383:1413-1424.
6. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with preserved ejection
fraction. N Engl J Med. 2022; 387:1089-1098.
7. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of
cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of
cardiovascular outcome trials. Lancet. 2019; 393:31-39.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure. Eur Heart J. 2021; 42:3599-3726.
9. . Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney
disease. N Engl J Med. 2020; 383:1436-1446.
10. Butler J, Zannad F, Filippatos G, et al. Cardiovascular effects of SGLT2 inhibitors in heart failure:
mechanisms and clinical implications. Nat Rev Cardiol. 2022; 19:279-294.
11. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening
heart failure. N Engl J Med. 2021; 384:117-128.
12. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of
the-art review. Diabetology. 2018; 61:2108-2117.